Omeza Complete Matrix
(OCM™)
OCM™ is a wound care drug-device comprised of fish peptides infused with cod liver oil, which acts as an anhydrous skin protectant. When applied to a wound surface, the matrix is naturally incorporated into the wound over time. OCM™ is designed for intimate contact with both regular and irregular wound beds, to provide a conducive environment for the patient’s natural wound healing process.
OCM™ is indicated for the management of wounds including: partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Moh’s surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, superficial partial thickness burns, skin tears) and draining wounds.
First of its kind drug-device
- First in class formulation with multi-modal mechanisms of action
- Treats most types of chronic wounds and patients
OCM™ is created through a proprietary process
- An amorphous solid covers the wound bed (including tunnels)
- This malleable sheet provides support for comprehensive healing
OCM™ Contains
Cold water fish peptides
- Building blocks for tissue regeneration
- Cell signaling molecules
Pharmaceutical-Grade components
- Natural, non-cytotoxic components known to be antimicrobial
- Reduces biofilm impact
- Reduces inflammation
- Increases proliferation
- Supports remodeling
Non-Healing wounds
Chronic non-healing wounds pose significant challenges due to an elevated inflammatory response caused in part by bacterial contamination. These wounds lead to billions being spent in the health care system worldwide.
The in-vitro study conducted was a zone of inhibition test with the two microbes at 104 Log CFU/mL inoculated on Tryptic soy agar with 5% sheep blood (TSAII) plates. Treatments used were multimodal wound matrix (MWM), Mupirocin (Positive control for MRSA), Silver Sulfadiazine (Positive Control for PA), Petrolatum and Sterile Saline (both serving as NegativeControls). Treatments were allowed to diffuse into the agar for 3 hours and then were incubated for 24 hours at 37°C. The in-vivo study utilized a deep dermal porcine wound model (22 × 22 × 3 mm) created on six animals. Three animals were inoculated with MRSA USA300 and the other three with PA27312 with each allowing a 72-h biofilm formation. After 72 h, baseline wounds were assessed for bacterial concentration and all remaining wounds were treated with either MWM alone, Silver Treatment or Untreated Control. Wounds were assessed on days 4, 8 and 12 after treatment application for microbiological analysis. In-vitro, MWM exhibited significant inhibition of MRSA USA300 and PA27312 growth when compared to negative controls (p ≤ 0.05). Likewise, in-vivo, the MWM-treated wounds exhibited a significant (p ≤ 0.05) bacterial reduction compared to all other treatment groups, especially on days 8 and 12 for both pathogens. MWM demonstrated promise in addressing colonized wounds with biofilms.
- OCM™ significantly inhibits Methicillin Resistant Staphylococcus (MRSA) and Pseudomonas Aeruginosa in an in vivo porcine wound model at Day 4, 8, 12 and exceeds healing
All necessary regulatory documentation, instructions for use, published studies, patient education tools, etc. (as applicable) can be provided upon request by contacting cs@spartanmedical.com or (888) 240-8091. We are available at any time to meet with providers and staff to answer any questions about Spartan Medical’s entire portfolio of advanced medical solutions.
